The Effects of Lemborexant on the Ability to Sleep During Daytime

PHASE2RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 11, 2024

Primary Completion Date

September 1, 2025

Study Completion Date

September 1, 2025

Conditions
Shift-Work Sleep Disorder
Interventions
DRUG

Lemborexant 5 MG [Dayvigo]

Lemborexant 5 mg will be taken orally once per day just prior to initiating laboratory-supervised daytime sleep episodes, for three consecutive days, within a few minutes before going to bed, with at least seven hours remaining before the planned time of awakening.

OTHER

Matching Placebo

Matching placebo will be taken orally once per day just prior to initiating laboratory-supervised daytime sleep episodes, for three consecutive days, within a few minutes before going to bed, with at least seven hours remaining before the planned time of awakening.

Trial Locations (1)

H4J 1C5

RECRUITING

CIUSSS du Nord de l'ile de Montreal (CIUSSS-NIM) - Hôpital du Sacré-Cœur de Montréal (HSCM), Montreal

All Listed Sponsors
lead

Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal

OTHER